Personalizing Treatment in Relapsed/Refractory Multiple Myeloma: The Evolving Role of Antibody-Drug Conjugates and Bispecific Antibodies

This activity was originally presented live at the 2025 Oncology Pharmacists Connect Conference in Austin, Texas.

Program Description

The treatment of relapsed/refractory multiple myeloma (RRMM) is rapidly changing, with bispecific antibodies (BsAbs) and antibody-drug conjugates (ADCs) emerging as promising alternatives. However, oncology pharmacists face challenges in staying current with these therapies, particularly in interpreting complex clinical data. Many pharmacists struggle with sequencing therapies and managing adverse event prophylaxis. This session aims to provide oncology pharmacists with the necessary tools to stay current with guidelines, assess the role of BsAbs and ADCs in treating RRMM, and manage complexities of adverse event prophylaxis. Key highlights will include in-depth reviews of BCMAxCD3-targeting BsAbs, GPRC5DxCD3-targeting BsAbs, and BCMA-directed ADCs (belantamab mafodotin), along with emerging therapies and targets. Oncology pharmacists will gain perspectives supporting the individualized treatment selection for patients who are refractory or ineligible for chimeric antigen receptor (CAR) T-cell therapy, considering patient- and disease-specific factors, and navigating newly published sequencing guidance. A significant focus will be placed on proactive management of adverse events, including strategies to mitigate ocular toxicities, cytokine release syndrome, and infection risks.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: July 2, 2025
Expiration date: July 2, 2026

Time to complete activity: 1.0 hour

Learner level: Advanced
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Analyze emerging data on bispecific antibodies (BsAbs) and antibody-drug conjugates (ADCs) in relapsed or refractory multiple myeloma (RRMM)
• Document recently published guidance and key patient-specific factors to guide the use of ADCs and BsAbs in RRMM
• Apply best practices for managing ocular adverse effects (AEs) of ADCs in MM, focusing on prevention and patient education to improve adherence to eye care regimens
• Examine preventive measures for BsAb-related AEs, considering the latest clinical findings and expert guidance

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-25-222-H01-P. The activity is available for CE credit through July 2, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

James Davis, PharmD, BCOP , has the following financial relationships with commercial interests to disclose:
Consultant: Bristol Myers Squibb, GSK, Janssen Pharmaceuticals; Speakers Bureau: Janssen Pharmaceuticals

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Daphne Davis, PharmD, BCOP; Crissy Wilson; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms